Volume | 351,553 |
|
|||||
News | - | ||||||
Day High | 0.756 | Low High |
|||||
Day Low | 0.7251 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spruce Biosciences Inc | SPRB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.75 | 0.7251 | 0.756 | 0.7542 | 0.7444 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,319 | 351,553 | $ 0.7424972 | $ 261,027 | - | 0.6711 - 5.95 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:52:08 | 20 | $ 0.7518 | USD |
Spruce Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
30.53M | 40.71M | - | 10.09M | -47.92M | -1.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spruce Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.7073 | 0.7572 | 0.69 | 0.7253944 | 405,917 | 0.0462 | 6.53% |
1 Month | 0.831 | 0.8398 | 0.6711 | 0.7216943 | 562,915 | -0.0775 | -9.33% |
3 Months | 4.41 | 5.95 | 0.6711 | 1.40 | 1,388,745 | -3.66 | -82.91% |
6 Months | 1.10 | 5.95 | 0.6711 | 1.63 | 786,139 | -0.3465 | -31.50% |
1 Year | 2.31 | 5.95 | 0.6711 | 1.70 | 446,939 | -1.56 | -67.38% |
3 Years | 15.51 | 16.2099 | 0.6711 | 3.35 | 649,262 | -14.76 | -95.14% |
5 Years | 17.00 | 35.60 | 0.6711 | 3.73 | 558,411 | -16.25 | -95.57% |
Spruce Biosciences Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders. The company is developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). |